Journal of Leukemia & Lymphoma 2018;27(12):721-724

doi:10.3760/cma.j.issn.1009-9921.2018.12.005

Progress of chemotherapy-free regimens in follicular lymphoma

Jin MAO 1 ; Wei XU

Affiliations

+expand

Keywords

Lymphoma,follicular; Targeted therapy; Therapy; Progress

Country

China

Language

Chinese

Abstract

Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma (HL) originating from the follicular germinal center. Chemotherapy could cause a variety of adverse reactions, such as infection, secondary malignancies and myelosuppression. The new "chemotherapy-free" treatment can significantly improve the tolerance of FL patients. The emergence of chemotherapy-free regimens such as venetoclax combined with rituximab and new non-chemotherapy drugs such as anti-CD20 and anti-CD3 bispecific IgG4 antibody REGN1979 provide new therapeutic regimens and ideas for primary and relapsed/refractory FL patients.